Small-Fiber Neuropathy/Neuronopathy Associated With Celiac Disease

Skin Biopsy Findings

Thomas H. Brannagan III, MD; Arthur P. Hays, MD; Steven S. Chin, MD, PhD; Howard W. Sander, MD; Russell L. Chin, MD; Paul Magda, DO; Peter H. R. Green, MD; Norman Latov, MD, PhD

Background: Celiac disease (CD) is increasingly recognized in North America and is associated with a peripheral neuropathy.

Objective: To report the clinical characteristics and skin biopsy results in patients with CD and small-fiber neuropathy symptoms.

Design: Case series.

Setting: Academic peripheral neuropathy clinic.

Patients: Eight patients with CD and neuropathy symptoms.

Intervention: Three-millimeter punch biopsy using the panaxonal marker protein gene product 9.5 to assess epidermal nerve fiber (ENF) density and a gluten-free diet.

Main Outcome Measure: Clinical data and ENF density.

Results: All patients had asymmetric numbness and paresthesias. Three had more prominent involvement of hands than feet, and 3 had facial numbness. Celiac disease was diagnosed in 5 after their neuropathy began. The following serum antibody levels were elevated: tissue transglutaminase (n=6), IgA gliadin (n=4), and IgG gliadin (n=7). Results of nerve conduction studies were normal in 7 patients. One patient had mildly reduced sural amplitudes. The ENF density was reduced in 5 patients. The ENF density was at the low limit of the normal range in 3 additional patients, 2 of whom had morphologic changes in axons. Three patients had decreased ENF density at the thigh or forearm, which was more severe than at the distal leg, compatible with a non–length-dependent process. Four reported improvement with a gluten-free diet. One had no improvement after 4 months. Symptoms developed in 2 while receiving a gluten-free diet.

Conclusions: Patients with CD may have a neuropathy involving small fibers, demonstrated by results of skin biopsy. The pattern of symptoms, with frequent facial involvement and a non–length-dependent pattern on skin biopsy findings, suggests a sensory ganglionopathy or an immune-mediated neuropathy. Improvement of symptoms in some patients after initiating a gluten-free diet warrants further study.

Arch Neurol. 2005;62:1574-1578

(C)2005 American Medical Association. All rights reserved.
Eight patients (6 women) with neuropathy symptoms that began at ages ranging from childhood to 59 years underwent evaluation (Table 1). All patients had asymmetric numbness or paresthesias, although in some the asymmetry was minimal and close to a length-dependent pattern. Three patients had more prominent involvement of the hands than feet, and 3 had facial numbness. Ankle reflexes were normal in 5 patients and diminished in 3. Celiac disease was diagnosed in 5 patients after their neuropathy began. We saw 3 patients for neurological evaluation before their diagnosis of CD. An additional patient saw another neurologist before the diagnosis of CD, although we did not perform a neurological evaluation until after the diagnosis. One patient received a diagnosis as an infant, and neuropathy developed after a long period of dietary noncompliance in the middle of his sixth decade of life. In the patients with neuropathy and CD, no other cause of neuropathy was found. All patients had levels of vitamin B12 and thyrotropin within reference ranges and no evidence of a monoclonal protein. Results of a 2-hour glucose tolerance test did not show diabetes mellitus or impaired glucose tolerance in the 7 patients who underwent the test.

Tissue transglutaminase antibody levels were elevated in 6 patients (68–186 U; reference range, <20 U) (Table 2). Levels of IgA gliadin antibodies were elevated in 4 patients (62–164 U; reference range, <20 U). Levels of IgG gliadin antibodies were elevated in 7 patients (33–138 U; reference range, <20 U). One patient had only an elevated IgG gliadin antibody level of 33 U.

Only 1 patient had diarrhea, the classic symptom of CD. Three additional patients had abdominal bloating or cramping. One patient had only constipation. The remaining 3 patients had no gastrointestinal tract symptoms.

All patients received a diagnosis of CD on the basis of duodenal biopsy results, with partial or complete

### Table 1. Clinical Characteristics of 8 Patients With Symptoms of Small-Fiber Neuropathy

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Sensory Symptoms</th>
<th>Results of Sensory Examination</th>
<th>Sural Nerve Conductions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Light Touch</td>
<td>Position/Vibration</td>
</tr>
<tr>
<td>1</td>
<td>Tingling in L arm; L leg→R leg</td>
<td>Absent in fingers and toes</td>
<td>Normal ↓ in hands; feet</td>
</tr>
<tr>
<td>2</td>
<td>Burning pain, tightness, feeling as if “coming out of snow into warmth,” onset in L foot, followed by R foot, followed by R hand and intermittent right-sided facial and left-sided tongue numbness</td>
<td>↓</td>
<td>Normal ↓ (moderately)</td>
</tr>
<tr>
<td>3</td>
<td>Stabbing, tingling, pins and needles, itchiness, with onset in R foot, months later L foot, then face and arms in numbness, tingling burning (R foot→L foot)</td>
<td>↓ (L foot→R foot); normal in hands</td>
<td>Normal ↓ (mild in feet)</td>
</tr>
<tr>
<td>4</td>
<td>Numbness, tingling, burning (R foot→L foot)</td>
<td>Normal</td>
<td>Normal ↓ (mild in R toes)</td>
</tr>
<tr>
<td>5</td>
<td>Burning, stabbing, tingling, onset in arms and legs simultaneously, face, torso involved, felt hot and raw</td>
<td>Normal</td>
<td>Normal ↓ (mild in toes)</td>
</tr>
<tr>
<td>6</td>
<td>Burning and tingling in hands→feet</td>
<td>Normal</td>
<td>Normal ↓ (mild in toes)</td>
</tr>
<tr>
<td>7</td>
<td>Numbness in hands, before legs</td>
<td>↓ (L side→R hands and R feet)</td>
<td>Normal/normal</td>
</tr>
<tr>
<td>8</td>
<td>Severe pins-and-needles tingling in feet &gt;hands</td>
<td>↓ (L&gt;R hands)</td>
<td>Normal/normal</td>
</tr>
</tbody>
</table>

Abbreviations: CV, conduction velocity; L, left; R, right; NP, not performed.

**METHODS**

The Institutional Review Board of the Weill Medical College of Cornell University, New York, NY, approved this study. Patients included those with CD diagnosed as having partial or total villous atrophy on results of duodenal biopsy and symptoms of neuropathy. Patients were seen at the Peripheral Neuropathy Center of Cornell University. No patients from our previous publication are included. A 3-mm punch biopsy specimen was obtained 10 cm proximal to the lateral malleolus and at the lateral proximal thigh. A biopsy specimen was obtained 10 cm proximal to the lateral malleolus and at the lateral proximal thigh. A biopsy specimen was obtained from the extensor side of the distal forearm in 1 patient. Cryo-sections were cut at a thickness of 50 µm and stained by an immunoperoxidase method using polyclonal antibodies directed against the panaxonal marker protein gene product 9.5. Total ENFs are counted in 5 different tissues sections and expressed as the number per millimeter of length of the epidermis. We compared the mean number with published normative data. We excluded a ninth patient with an elevated fasting glucose level and CD.

**RESULTS**

©2005 American Medical Association. All rights reserved.
Results of motor nerve conduction studies (median, ulnar, tibial, and peroneal) were normal in all patients. The tibial and peroneal nerve studies were performed bilaterally in 7 patients. Results of sural nerve conduction studies were normal in 7 patients, with an orthodromic sural amplitude of 10 to 27 µV (reference range, ≥60 µV). Six patients had bilateral sural studies. Patient 2 had mildly reduced evoked response amplitudes of the sural nerve. Results of ulnar sensory nerve conduction studies were normal in all patients. Results of median sensory nerve conduction studies were normal in all patients. Results of motor nerve conduction studies (median, ulnar, tibial, and peroneal) were normal in all patients. The lack of response to a GFD could be due to many reasons. Patients could be noncompliant. Even minimal gluten exposure can cause a persistent immune response. The lack of improvement could also be due to an insufficient follow-up period, incomplete recovery after axonal or neuronal loss, differences in the methods of assessing neuropathy improvement, or different mechanisms of neuropathy that are unresponsive to the GFD. Antiganglioside antibodies have been demonstrated in patients with CD may have a neuropathy involving small fibers, which can be demonstrated by results of a skin biopsy assessing ENF density. The neuropathy may be the presenting symptom of the disorder and may occur without gastrointestinal tract symptoms. The pattern of symptoms, with frequent facial involvement, multifocal clinical involvement, and a non–length-dependent pattern on skin biopsy, suggests the possibility of an immune-mediated process or sensory ganglionopathy. Although we have no pathological confirmation of a ganglionopathy, antigliadin antibodies have been reported to bind to Purkinje cells and could potentially also bind to dorsal root ganglion neurons.

Improvement in symptoms in some patients after initiating a GFD warrants further study. Not all of our patients improved. The benefit of a GFD on peripheral neuropathy is unknown. Some previous investigators have reported improvement in neuropathy with the GFD. Other investigators, however, have reported that the peripheral neuropathy does not respond to a GFD. Even patients following a GFD who are in clinical and histological remission may have a clinical or subclinical neuropathy.

Patients with CD may have a neuropathy involving small fibers, which can be demonstrated by results of a skin biopsy assessing ENF density. The neuropathy may be the presenting symptom of the disorder and may occur without gastrointestinal tract symptoms. The pattern of symptoms, with frequent facial involvement, multifocal clinical involvement, and a non–length-dependent pattern on skin biopsy, suggests the possibility of an immune-mediated process or sensory ganglionopathy. Although we have no pathological confirmation of a ganglionopathy, antigliadin antibodies have been reported to bind to Purkinje cells and could potentially also bind to dorsal root ganglion neurons.

Improvement in symptoms in some patients after initiating a GFD warrants further study. Not all of our patients improved. The benefit of a GFD on peripheral neuropathy is unknown. Some previous investigators have reported improvement in neuropathy with the GFD. Other investigators, however, have reported that the peripheral neuropathy does not respond to a GFD. Even patients following a GFD who are in clinical and histological remission may have a clinical or subclinical neuropathy.

The lack of response to a GFD could be due to many reasons. Patients could be noncompliant. Even minimal gluten exposure can cause a persistent immune response. The lack of improvement could also be due to an insufficient follow-up period, incomplete recovery after axonal or neuronal loss, differences in the methods of assessing neuropathy improvement, or different mechanisms of neuropathy that are unresponsive to the GFD. Antiganglioside antibodies have been demonstrated in 65% of patients with celiac neuropathy, but it is unknown whether these antibodies are pathogenic or whether the levels fall once a GFD is strictly followed. Most investigators have reported that some patients with symptoms of a small-fiber neuropathy may have nor-

---

**Table 2. Antibodies in Patients With Small-Fiber Neuropathy and CD**

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Tranglutaminase, U</th>
<th>IgA Gliadin, U</th>
<th>IgG Gliadin, U</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>83</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>11</td>
<td>33</td>
</tr>
<tr>
<td>3</td>
<td>186</td>
<td>112</td>
<td>138</td>
</tr>
<tr>
<td>4</td>
<td>17</td>
<td>110</td>
<td>63</td>
</tr>
<tr>
<td>5</td>
<td>68</td>
<td>7</td>
<td>35</td>
</tr>
<tr>
<td>6†</td>
<td>75 (10)</td>
<td>164 (9)</td>
<td>55 (21‡)</td>
</tr>
<tr>
<td>7</td>
<td>60</td>
<td>62</td>
<td>87</td>
</tr>
<tr>
<td>8</td>
<td>65</td>
<td>15</td>
<td>121</td>
</tr>
</tbody>
</table>

Abbreviation: CD, celiac disease.

*Abnormal values are in boldface type. Unless otherwise indicated, the reference range for all antibody levels is less than 20 U.

†Patient 6 had elevated transglutaminase and IgG and IgA gliadin antibody levels (boldface values) at the time of CD diagnosis. Neuropathic symptoms developed after she started a gluten-free diet. The values in parentheses were obtained during the neuropathy evaluation.

‡Reference range, <24.

---

©2005 American Medical Association. All rights reserved.
mal ENF density. Some of these patients have morphologic changes that may be predegenerative, preceding loss of nerve fibers. In 3 of our patients, the ENF density was in the low range of normal, but in 2 there were morphologic changes, including abnormal axonal swelling, excessive branching, and a horizontal orientation of nerve fibers.

Celiac neuropathy may occur in patients with silent CD (those without prominent gastrointestinal tract symptoms). The diagnosis is aided by the presence of antibodies associated with CD; however, most of our patients had only some of the antibodies present, and could have been missed if only single antibody levels such as transglutaminase were measured, emphasizing the role of performing a celiac antibody panel.

Several recent prospective studies have noted a high prevalence of neuropathy in patients with CD. A prospective study of 176 patients from a gastrointestinal unit found that 52% had signs of neuropathy and 49% had symptoms of neuropathy. Fifty-two percent had hypo-reflexia; 18% had decreased vibration; 49% had cramps; 44% had paresthesias; and 31% had weakness. Another study of patients with CD who consumed a GFD for at least 2 years found that 35% complained of numbness and paresthesias, and 23% had electromyographic evidence of a chronic neuropathy.

In our previous series, some patients had a large-fiber neuropathy, confirmed by abnormal results of nerve conduction studies. Among patients with small-fiber neuropathy, it has been estimated that the disease is idiopathic in 90%, although results of a glucose tolerance test can identify additional

Table 3. Epidermal Nerve Fiber Density

<table>
<thead>
<tr>
<th>Patient No./Age, y</th>
<th>ENF Density, No. of ENF/mm</th>
<th>Distal Leg*</th>
<th>Proximal Thigh†</th>
<th>Distal Forearm‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/61 4.7</td>
<td>4.7</td>
<td>6.9</td>
<td>NP</td>
<td></td>
</tr>
<tr>
<td>2/42 Reduced</td>
<td>Low normal</td>
<td>4.8</td>
<td>NP</td>
<td></td>
</tr>
<tr>
<td>3/50 5.5</td>
<td>2.1</td>
<td>10.2</td>
<td>NP</td>
<td></td>
</tr>
<tr>
<td>5/41 6.4</td>
<td>21.5</td>
<td>4.4</td>
<td>NP</td>
<td></td>
</tr>
<tr>
<td>6/25 6.9</td>
<td>7.2</td>
<td>10.5</td>
<td>NP</td>
<td></td>
</tr>
<tr>
<td>7/29 9</td>
<td>5.5§</td>
<td>NP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8/16 7.3§</td>
<td>5.5§</td>
<td>NP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ENF, epidermal nerve fiber; NP, not performed.

*The normal mean (fifth percentile of normal) is 13.8 ENF/mm (3.8 ENF/mm).
†The normal mean (fifth percentile of normal) is 21.1 ENF/mm (5.2 ENF/mm).
‡The normal mean is 17.1 ENF/mm.
§The normal values for ages 10 to 19 years at the distal leg are 20.3 ENF/mm and 31.6 ENF/mm at the proximal thigh.

Figure. Fixed cryosections of skin biopsy specimens from the distal part of the leg of a healthy subject (A) and patient 4 (B), who has an abnormally low epidermal nerve fiber density (immunoperoxidase stain of protein gene product 9.5 [a panaxonal marker], original magnification ×400).
patients with impaired glucose tolerance or diabetes mellitus. Celiac disease may be another identifiable cause of peripheral neuropathy and particularly of small-fiber neuropathy. Results of a skin biopsy could help identify these patients in prospective trials to identify the frequency of CD as a cause of idiopathic neuropathy.

Accepted for Publication: January 31, 2005.

Correspondence: Thomas Brannagan III, MD, Peripheral Neuropathy Center, Department of Neurology and Neuroscience, Weill Medical College of Cornell University, 635 Madison Ave, Suite 400, New York, NY 10022 (THB2006@med.cornell.edu).

Author Contributions: Study concept and design: Brannagan and Sander. Acquisition of data: Brannagan, Hays, S. S. Chin, Sander, R. L. Chin, Magda, Green, and Latov. Analysis and interpretation of data: Brannagan, Sander, and R. L. Chin. Drafting of the manuscript: Brannagan and Sander. Critical revision of the manuscript for important intellectual content: Hays, S. S. Chin, Sander, R. L. Chin, Magda, Green, and Latov. Administrative, technical, and material support: Brannagan, Hays, S. S. Chin, Sander, R. L. Chin, Magda, and Green. Study supervision: Brannagan and Sander.

Previous Presentation: This paper was presented in part in abstract form at the 56th Annual Meeting of the American Academy of Neurology; April 28, 2004; San Francisco, Calif.

REFERENCES